Magnetic resonance imaging measures of brain atrophy in multiple sclerosis.
about
The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple SclerosisEvidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—clinical implementation in the diagnostic processMRI in multiple sclerosis: what's inside the toolbox?Longitudinal whole-brain atrophy and ventricular enlargement in nondemented Parkinson's disease.Design, data management, and population baseline characteristics of the PERFORM magnetic resonance imaging project.Cerebral atrophy after traumatic white matter injury: correlation with acute neuroimaging and outcome.Review: Mitochondria and disease progression in multiple sclerosisA hybrid geometric-statistical deformable model for automated 3-D segmentation in brain MRI.Measuring brain atrophy with a generalized formulation of the boundary shift integral.Sera from remitting and secondary progressive multiple sclerosis patients disrupt the blood-brain barrierPredictive value of imaging markers at multiple sclerosis disease onset based on gadolinium- and USPIO-enhanced MRI and machine learning.Methemoglobin is an endogenous toll-like receptor 4 ligand-relevance to subarachnoid hemorrhage.Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine.Role of neuroimaging in multidisciplinary approach towards Non-Alzheimer's dementia.Progression of non-age-related callosal brain atrophy in multiple sclerosis: a 9-year longitudinal MRI study representing four decades of disease development.Effect of Fingolimod on Brain Volume Loss in Patients with Multiple Sclerosis.Optical coherence tomography in optic neuritis and multiple sclerosis: a review.Gray Matter Pathology in MS: Neuroimaging and Clinical Correlations.The relation between inflammation and neurodegeneration in multiple sclerosis brains.Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.Neuroimaging of rapidly progressive dementias, part 2: prion, inflammatory, neoplastic, and other etiologies.Imaging in multiple sclerosis: A new spin on lesions.The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multipCan rate of brain atrophy in multiple sclerosis be explained by clinical and MRI characteristics?Strokes in Sneddon syndrome without antiphospholipid antibodies.Magnetic resonance imaging measures of brain and spinal cord atrophy correlate with clinical impairment in secondary progressive multiple sclerosis.Modelling the natural history of primary progressive multiple sclerosis.Clinically benign multiple sclerosis despite large T2 lesion load: can we explain this paradox?Brain volume and diffusion markers as predictors of disability and short-term disease evolution in multiple sclerosis.Association between cytokines and cerebral MRI changes in the aging brain.Fatigue and progression of corpus callosum atrophy in multiple sclerosis.Cytokine Profile in Patients with Progressive Multiple Sclerosis and Its Association with Disease Progression and Disability.MRI Markers and Functional Performance in Patients With CIS and MS: A Cross-Sectional Study
P2860
Q28073377-7E163D67-6429-4430-94A7-BF0E14A7AD8DQ29542960-7E950D4B-0F91-430A-A123-07C72BE316A7Q31132442-B775F220-3543-47E7-A1CB-E8C5ECD15DC2Q33754677-1C1A98A3-4A48-49CD-8101-4D3DB5132218Q33762413-41A7E21F-A64B-4374-B4A1-01CBA3ADF617Q33805253-BA0C51FE-2058-4FE4-BDCE-0BD6552ACCBFQ34308687-65D925DD-1693-4EB4-9189-A30FEBFE563BQ34746732-0FC1EB01-3C04-4901-B49D-85761AC86A70Q34889037-E3ABEE81-8F45-4B55-BB07-A4EF661340A5Q35136280-6AE3ADB1-7AD6-497B-BF32-844BE70CAFD3Q35137514-2FBFA40D-4B9C-414E-9EA4-A3814E5373CFQ35380756-0E7DE2D1-AD4B-4390-A713-EEF257247537Q35997017-88A205A4-222C-432C-837B-6816AEFABF5FQ36059072-181C27AB-5B5D-422F-B22E-79F61BDD2B71Q36143320-E19336FB-2E3F-4092-8F26-FF76FD42A4A8Q36293431-B6C84326-190F-459D-9C53-7905492023ECQ36895990-3D05C2B4-3D1C-4D12-B895-809CF422C0CBQ37002903-E7A17827-DCB0-4D09-9E1A-662808C0BF2CQ37181308-C421DAC6-85E2-4132-A454-DBF6CE95F808Q37343849-45D47A80-7AC3-4258-BAAC-89DDA521A519Q38081869-BD3C260B-288D-483E-AFEE-52A99720D199Q38910256-C71D227B-0450-4526-AB1C-7033550A2FC4Q39195628-A2774C07-C501-450D-904D-16488C61181AQ40017560-66394830-E789-4600-851F-1B4E8B470F86Q41516486-FAF7598C-FC84-4F14-8778-1C01B2E51341Q43606941-9B7B0854-2558-4C27-8DA0-7FA2AB0CCEC3Q43923618-E4CBDD94-E6A1-40A1-BF54-E6A24C90FBCDQ46912034-F513D363-B3B4-43B0-A518-CA97555C81ACQ48632417-1C55BF10-8F46-4FCB-931B-8451FF01536AQ48765609-B63D5465-72AA-4EA1-A2E6-046482058071Q51461532-9462EF9E-36DC-4FEC-AF16-00F55658936CQ52143402-F30712B4-0A85-486C-BBAB-2A39FA0820C5Q58694089-62985A43-3D06-4227-B15F-9C4F10BA18DE
P2860
Magnetic resonance imaging measures of brain atrophy in multiple sclerosis.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Magnetic resonance imaging measures of brain atrophy in multiple sclerosis.
@ast
Magnetic resonance imaging measures of brain atrophy in multiple sclerosis.
@en
type
label
Magnetic resonance imaging measures of brain atrophy in multiple sclerosis.
@ast
Magnetic resonance imaging measures of brain atrophy in multiple sclerosis.
@en
prefLabel
Magnetic resonance imaging measures of brain atrophy in multiple sclerosis.
@ast
Magnetic resonance imaging measures of brain atrophy in multiple sclerosis.
@en
P2860
P356
P1476
Magnetic resonance imaging measures of brain atrophy in multiple sclerosis.
@en
P2093
David H Miller
P2860
P304
P356
10.1002/JMRI.20550
P577
2006-05-01T00:00:00Z